X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 22, 2020

SARS-CoV-2 Vaccines – Primary Packaging Challenges

Developing a SARS-CoV-2 vaccine presents numerous and unprecedented challenges; prominent among them are greatly accelerated timelines. Ordinarily for a new drug product, there is sufficient time for selection/evaluation of the vial/stopper packaging system – one that guarantees quality and safety from manufacture through delivery. This is not the case for a SARS-CoV-2 vaccine where the primary packaging system must be chosen quickly, creating a higher risk.
Page McAndrew

Page McAndrew PhD.

Director, Scientific Communications

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts

    March 13, 2020

    Multiple Benefits of Elastomeric Closures with FluroTec® Barrier Film

    Gabrielle Gehron

    Gabrielle Gehron

    Associate Technical Account Specialist, TCS

    Fluoropolymer

    December 06, 2019

    Advantages of Fluoropolymer-Laminated Components

    Candice Sun

    Candice Sun

    Specialist, Scientific Affairs, CN

    B2 Coating Stoppers

    March 04, 2019

    The Smart Solution When Silicone Oil is an Issue

    Simon Meurer

    Simon Meurer

    Manager, TCS, Commercial

    FluroTec Barrier Film Coating

    January 29, 2019

    Effective Drug Protection for Plungers in a Prefillable Syringe System

    Christa Jansen-Otten

    Christa Jansen-Otten

    Director, Product Mgmt, PFS & Delivery

    Load more